Moving from Transition to Implementation

For many manufacturers, the months leading up to February 2026 were dominated by gap assessments, internal audits, and process reviews. Organizations that invested early in aligning with ISO 13485 are likely to find themselves in a stronger position, with a more coherent and globally consistent quality system already in place. However, for a significant number of companies, particularly smaller manufacturers and those with historically U.S.-focused operations, the transition period often ended before the work was complete.

Common gaps emerging in the post-transition landscape include inconsistent risk management practices across the product lifecycle, incomplete supplier control documentation, and training programs that have not yet been updated to reflect new regulatory expectations. In many cases, the challenge is not a lack of intention but a lack of integration: quality system elements that exist in isolation rather than functioning as a unified, risk-based framework.

The distinction matters because under the QMSR, the FDA is looking not merely at whether individual procedures exist, but whether the overall quality system is cohesive, risk-informed, and capable of consistently producing safe and effective devices.

Ensuring Inspection Readiness Under QMSR

FDA inspections have not gone away under QMSR, and if anything, the stakes are higher. The new regulation introduces a more nuanced inspection model, which draws heavily on the documentation and risk management principles embedded in ISO 13485. Investigators will expect to see evidence of a living quality system – one that identifies risks proactively, responds to nonconformances systematically, and maintains robust records across the entire product lifecycle.

Manufacturers should anticipate that inspectors will probe the alignment between their ISO 13485 certification and their FDA compliance posture. A third-party ISO 13485 certificate does not guarantee FDA approval, nor does it substitute for an FDA inspection. What it does provide is a credible foundation, demonstrating a commitment to internationally recognized quality principles that investigators can build upon. Companies that can clearly articulate how their certified quality management systems map to QMSR requirements will be better positioned to navigate early inspections with confidence.

Documentation remains a critical area of focus. Under the QMSR, expectations around records, traceability, and design history files are more closely aligned with ISO 13485, meaning that manufacturers accustomed to the legacy QSR framework may need to revisit how they structure and retain records. Audit trails, corrective and preventive action (CAPA) records, and post-market surveillance data will all be subject to scrutiny.

Managing Remaining Gaps: A Practical Approach

For manufacturers still finalizing their QMSR alignment, a structured and prioritized approach is essential. The first step is to confirm where gaps remain by conducting a thorough review against both ISO 13485 requirements and the specific expectations of QMSR. Not all gaps carry equal weight, and remediation should be prioritized based on patient safety risk and regulatory exposure, with the highest-risk areas addressed first.

From there, the focus should shift to finalizing updates to procedures, training programs, and governance structures. Updating a document alone is insufficient; personnel at every level must understand what has changed and why. Workforce competency is a core requirement under ISO 13485, and it is an area that FDA investigators are likely to explore in detail.

Finally, conducting internal audits before an FDA inspection provides an opportunity to identify residual weaknesses and demonstrate a genuine commitment to continuous improvement, a principle that sits at the heart of both ISO 13485 and the QMSR.

Special Considerations

Not all manufacturers are navigating this transition from the same starting point. Small and mid-size companies, which often lack the dedicated regulatory resources of larger organizations, face particular challenges in building and maintaining a fully integrated QMS. For these businesses, leveraging external expertise through training, third-party certification support, or regulatory consulting can be a cost-effective way to close gaps without overstretching internal teams.

Companies entering the U.S. market for the first time under the QMSR framework may find themselves at an advantage if they already hold ISO 13485 certification. The convergence of FDA expectations with the international standard reduces the regulatory duplication that previously made entry to the U.S. market more burdensome. That said, these manufacturers should still invest time in understanding the specific nuances of FDA oversight, including the critical distinction between ISO 13485 certification and FDA inspection readiness.

For organizations managing quality systems across multiple regions, QMSR presents a strategic opportunity to move away from fragmented, jurisdiction-specific compliance towards a single, globally coherent framework, reducing duplication and administrative overhead in the process.

Looking Ahead

The introduction of QMSR is a clear signal of the direction in which medical device oversight is heading. As the industry looks towards AI-enabled devices, digital health technologies, and increasingly complex global supply chains, a robust and harmonized quality management system will be an essential foundation for both innovation and market access.

The manufacturers that emerge strongest from this transition will be those that treat the QMSR as an operational framework to be embraced rather than a compliance burden to be managed. A mature, well-implemented quality management system that aligns with ISO 13485 and meets FDA expectations is a strategic asset, and the organizations that recognize this early will be best placed to compete, innovate, and grow in the years ahead.